Repository logo

Infoscience

  • English
  • French
Log In
Logo EPFL, École polytechnique fédérale de Lausanne

Infoscience

  • English
  • French
Log In
  1. Home
  2. Academic and Research Output
  3. Journal articles
  4. In vitro synergistic action of TAT-RasGAP 317-326 peptide with antibiotics against Gram-negative pathogens
 
research article

In vitro synergistic action of TAT-RasGAP 317-326 peptide with antibiotics against Gram-negative pathogens

Vizzarro, Grazia  
•
Jacquier, Nicolas
December 1, 2022
Journal Of Global Antimicrobial Resistance

Objectives: Multidrug-resistant (MDR) bacteria are a continuously increasing threat for medicine, caus-ing infections recalcitrant to antibiotics. Antimicrobial peptides (AMPs) were identified as alternatives to antibiotics, being naturally occurring short peptides and part of the innate immune system of a vast ma-jority of organisms. However, the clinical application of AMPs is limited by suboptimal pharmacokinetic properties and relatively high toxicity. Combinatorial treatments using AMPs and classical antibiotics may decrease the concentrations of AMPs required for bacterial eradication, thus lowering the side effects of these peptides. Methods: Here, we investigate the in vitro efficiency of combinations of the recently described antimicro-bial peptide TAT-RasGAP317-326 with a panel of commonly used antimicrobial agents against three Gram-negative bacteria, Escherichia coli, Pseudomonas aeruginosa and Acinetobacter baumannii, using checker-board and time-kill assays. Results: We identified synergistic combinations towards all three bacteria and demonstrated that these combinations had an increased bactericidal effect compared to individual drugs. Moreover, combinations were also effective against clinical isolates of A. baumannii. Finally, combination of TAT-RasGAP317-326 and meropenem had a promising antibiofilm effect towards A. baumannii. Conclusions: Taken together, our results indicate that combinations of TAT-RasGAP317-326 with commonly used antimicrobial agents may lead to the development of new treatment protocols against infections caused by MDR bacteria.

  • Details
  • Metrics
Type
research article
DOI
10.1016/j.jgar.2022.10.003
Web of Science ID

WOS:000892228700010

Author(s)
Vizzarro, Grazia  
Jacquier, Nicolas
Date Issued

2022-12-01

Published in
Journal Of Global Antimicrobial Resistance
Volume

31

Start page

295

End page

303

Subjects

Infectious Diseases

•

Pharmacology & Pharmacy

•

antimicrobial peptides

•

biofilm

•

acinetobacter baumannii

•

pseudomonas aeruginosa

•

escherichia coli

•

antibiotic resistance

•

resistant acinetobacter-baumannii

•

mechanisms

•

pharmacokinetics

•

meropenem

•

biofilms

•

imipenem

•

colistin

•

strains

•

cells

Editorial or Peer reviewed

REVIEWED

Written at

EPFL

EPFL units
GHI  
Available on Infoscience
January 2, 2023
Use this identifier to reference this record
https://infoscience.epfl.ch/handle/20.500.14299/193526
Logo EPFL, École polytechnique fédérale de Lausanne
  • Contact
  • infoscience@epfl.ch

  • Follow us on Facebook
  • Follow us on Instagram
  • Follow us on LinkedIn
  • Follow us on X
  • Follow us on Youtube
AccessibilityLegal noticePrivacy policyCookie settingsEnd User AgreementGet helpFeedback

Infoscience is a service managed and provided by the Library and IT Services of EPFL. © EPFL, tous droits réservés